Figure 6
Figure 6. Donor T cell/DC interactions within recipient spleens on transplantation day +4. B6D2 recipients were lethally irradiated and administered 3 × 106 TCD BM cells from WT B6 donors with 4 × 106 CD25-depleted eGFP+ Tn cells from either WT B6 or CCR7−/− B6 donors on day 0. Recipients were killed on transplantation day +4, and their spleens removed for immunofluorescence microscopy. Images are taken from 1 of 3 representative WT Tn cell recipients and from 1 of 3 CCR7−/− Tn cell recipients. Donor cells are identified by their eGFP positivity (green). An anti-CD11c primary/Cy3-conjugated secondary antibody combination was used to visualize CD11c-expressing cells, which are predominantly DCs (red). (A,C) Recipients of WT Tn cells. (B,D) Recipients of CCR7−/− cells. Original magnifications, ×4 (A-B) and ×10 (C-D).

Donor T cell/DC interactions within recipient spleens on transplantation day +4. B6D2 recipients were lethally irradiated and administered 3 × 106 TCD BM cells from WT B6 donors with 4 × 106 CD25-depleted eGFP+ Tn cells from either WT B6 or CCR7−/− B6 donors on day 0. Recipients were killed on transplantation day +4, and their spleens removed for immunofluorescence microscopy. Images are taken from 1 of 3 representative WT Tn cell recipients and from 1 of 3 CCR7−/− Tn cell recipients. Donor cells are identified by their eGFP positivity (green). An anti-CD11c primary/Cy3-conjugated secondary antibody combination was used to visualize CD11c-expressing cells, which are predominantly DCs (red). (A,C) Recipients of WT Tn cells. (B,D) Recipients of CCR7−/− cells. Original magnifications, ×4 (A-B) and ×10 (C-D).

Close Modal

or Create an Account

Close Modal
Close Modal